• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

寡核苷酸和肽核酸系统中的主链修饰

Backbone modifications in oligonucleotides and peptide nucleic acid systems.

作者信息

De Mesmaeker A, Altmann K H, Waldner A, Wendeborn S

机构信息

Central Research Laboratories, Ciba-Geigy Ltd, Basel, Switzerland.

出版信息

Curr Opin Struct Biol. 1995 Jun;5(3):343-55. doi: 10.1016/0959-440x(95)80096-4.

DOI:10.1016/0959-440x(95)80096-4
PMID:7583633
Abstract

In the past year major advances have been made in the design, synthesis and characterization of two classes of modified oligonucleotides. In the first class, the phosphodiester backbone of 2'-deoxyribo-oligonucleotides has been replaced in several different ways. The second group represents a completely different type of oligonucleotide modification in which the backbone and the 2'-deoxyribose moieties are replaced by amino acids. These advances present new possibilities for the pharmaceutical applications of modified oligonucleotides in antisense strategies.

摘要

在过去的一年里,两类修饰寡核苷酸的设计、合成及特性研究取得了重大进展。在第一类中,2'-脱氧核糖寡核苷酸的磷酸二酯主链已通过几种不同方式被取代。第二类代表了一种完全不同类型的寡核苷酸修饰,其中主链和2'-脱氧核糖部分被氨基酸取代。这些进展为修饰寡核苷酸在反义策略中的药物应用带来了新的可能性。

相似文献

1
Backbone modifications in oligonucleotides and peptide nucleic acid systems.寡核苷酸和肽核酸系统中的主链修饰
Curr Opin Struct Biol. 1995 Jun;5(3):343-55. doi: 10.1016/0959-440x(95)80096-4.
2
Recent highlights in modified oligonucleotide chemistry.修饰寡核苷酸化学的近期亮点。
Org Biomol Chem. 2007 Oct 21;5(20):3260-75. doi: 10.1039/b709797m. Epub 2007 Sep 6.
3
Novel phosphoramidite building blocks in synthesis and applications toward modified oligonucleotides.用于合成修饰寡核苷酸的新型亚磷酰胺砌块及其应用。
Curr Med Chem. 2003 Oct;10(19):1973-91. doi: 10.2174/0929867033456909.
4
Triazole-linked Nucleic Acids: Synthesis, Therapeutics and Synthetic Biology Applications.三唑连接的核酸:合成、治疗和合成生物学应用。
Curr Org Synth. 2024;21(4):436-455. doi: 10.2174/1570179420666230502123950.
5
Backbone modification of nucleic acids: synthesis, structure and therapeutic applications.核酸的主链修饰:合成、结构及治疗应用
Curr Med Chem. 2001 Aug;8(10):1157-79. doi: 10.2174/0929867013372391.
6
Nucleic acids--genes, drugs, molecular lego and more.
Chimia (Aarau). 2010;64(1-2):14-6. doi: 10.2533/chimia.2010.14.
7
Chemical Development of Therapeutic Oligonucleotides.治疗性寡核苷酸的化学研发
Methods Mol Biol. 2019;2036:3-16. doi: 10.1007/978-1-4939-9670-4_1.
8
Modified Nucleic Acids: Expanding the Capabilities of Functional Oligonucleotides.修饰后的核酸:扩展功能性寡核苷酸的功能。
Molecules. 2020 Oct 13;25(20):4659. doi: 10.3390/molecules25204659.
9
Polyamine-oligonucleotide conjugates: a promising direction for nucleic acid tools and therapeutics.多胺-寡核苷酸缀合物:核酸工具和治疗学的一个有前景的方向。
Future Med Chem. 2015;7(13):1733-49. doi: 10.4155/fmc.15.90. Epub 2015 Oct 1.
10
Redesigning nucleic acids.重新设计核酸。
Pure Appl Chem. 1998 Feb;70(2):263-6. doi: 10.1351/pac199870020263.

引用本文的文献

1
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.小核酸疗法全景:作为下一代药物从实验室走向临床
Signal Transduct Target Ther. 2025 Mar 10;10(1):73. doi: 10.1038/s41392-024-02112-8.
2
Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency.靶向 miR-21 的 Mesyl 膦酰胺酸骨架修饰反义寡核苷酸,具有增强的体内治疗效力。
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32370-32379. doi: 10.1073/pnas.2016158117. Epub 2020 Dec 7.
3
Postnatal therapeutic approaches in genetic neurodevelopmental disorders.
遗传性神经发育障碍的产后治疗方法。
Neural Regen Res. 2021 Mar;16(3):414-422. doi: 10.4103/1673-5374.293133.
4
Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties.亚砜基磷酰胺酯反义寡核苷酸作为一种替代硫代磷酸酯的选择,具有改善的生化和生物学性质。
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1229-1234. doi: 10.1073/pnas.1813376116. Epub 2019 Jan 8.
5
Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs.当前治疗性 RNA 递送至细胞质及易位的挑战。
Nucleic Acid Ther. 2018 Jun;28(3):178-193. doi: 10.1089/nat.2017.0716.
6
Characterization of Byproducts from Chemical Syntheses of Oligonucleotides Containing 1-Methyladenine and 3-Methylcytosine.含1-甲基腺嘌呤和3-甲基胞嘧啶的寡核苷酸化学合成副产物的表征
ACS Omega. 2017 Nov 30;2(11):8205-8212. doi: 10.1021/acsomega.7b01482. Epub 2017 Nov 20.
7
Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2'-F RNA, and LNA in the context of Phi29 pRNA 3WJ.在Phi29 pRNA 3WJ背景下对硫代磷酸酯-DNA、DNA、RNA、2'-F RNA和锁核酸的热稳定性进行评估和比较。
RNA. 2018 Jan;24(1):67-76. doi: 10.1261/rna.063057.117. Epub 2017 Oct 19.
8
Amides are excellent mimics of phosphate internucleoside linkages and are well tolerated in short interfering RNAs.酰胺是磷酸酯核苷间连接的优秀模拟物,并且在短干扰RNA中具有良好的耐受性。
Nucleic Acids Res. 2014 Jun;42(10):6542-51. doi: 10.1093/nar/gku235. Epub 2014 May 9.
9
Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier.新型非核苷酸修饰物提高抗 miRNA 寡核苷酸的性能。
Mol Ther Nucleic Acids. 2013 Aug 27;2(8):e117. doi: 10.1038/mtna.2013.46.
10
RNA aptamer evolution: two decades of SELEction.RNA适配体的进化:二十年的指数富集配体系统进化技术
Int J Mol Sci. 2011;12(12):9155-71. doi: 10.3390/ijms12129155. Epub 2011 Dec 8.